Allogene Therapeutics中期研究显示血癌疗法延迟复发,股价盘前飙涨70%

美股速递
Apr 13

在Allogene Therapeutics Inc.(ALLO)公布其中期研究数据显示,该公司研发的血癌疗法能够显著延迟癌症复发后,其股价在盘前交易中一度飙升70%。

这项中期研究结果引发了市场对Allogene Therapeutics Inc. 疗法前景的强烈乐观情绪,投资者纷纷押注该创新疗法未来的商业化潜力。股价的剧烈波动反映出生物科技领域对突破性临床数据的敏感反应,也凸显了血癌治疗市场的巨大需求。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10